Diagnosis of a stroke is currently based mostly on non-laboratory testing. Researchers continue to try to find laboratory tests, such as stroke biomarkers, that could be used in stroke screening, diagnosis, treatment, and management. Two possibilities of biomarkers that could be helpful in risk assessment are Lp-PLA2 and N-methyl-D-aspartate neuroreceptors (NMDAR), while candidates for stroke diagnosis include antibodies to NR2A/2B and metalloproteinases (MMPs). It may be that a panel of biomarkers would be most effective as a diagnostic or risk assessment tool. These tests are not yet widely available, and their uses are mainly in research studies at present.
Other laboratory tests may be ordered to evaluate a patient suspected of having had a stroke or to rule it out, including:
This article was last reviewed on June 14, 2008.
This article was last modified on April 8, 2009.
The review date indicates when the article was last reviewed from beginning to end to ensure that it reflects the most current science. A review may not require any modifications to the article, so the two dates may not always agree.
The modified date indicates that one or more changes were made to the article. Such changes may or may not result from a full review of the article, so the two dates may not always agree.
On This Site